Neurocrine Biosciences (US:NBIX) — Company Overview, News & Financial Data
Neurocrine Biosciences is a biotech firm dedicated to treatments for neurologic, psychiatric, and endocrine disorders.
Neurocrine Biosciences
Neurocrine Biosciences (NASDAQ:NBIX) is a biotech firm engaged in discovering, developing, and commercializing innovative drugs for the treatment of neurologic, psychiatric, and endocrine-related diseases and disorders. The company focuses on advancing treatments for conditions with high unmet medical needs, such as Parkinson’s disease, tardive dyskinesia, and endometriosis. Neurocrine Biosciences is committed to improving patient outcomes through science-driven solutions. With a robust pipeline of potential therapies in various stages of clinical development, the company aims to deliver breakthrough medications that can significantly improve the quality of life for patients struggling with chronic and debilitating diseases.
Snapshot
Operations
Products and/or services of Neurocrine Biosciences
- Ingrezza, a breakthrough treatment for tardive dyskinesia offering significant symptom relief.
- Elagolix, developed for managing endometriosis and uterine fibroids, providing non-surgical treatment options.
- Collaborative research on gene therapy for neurological disorders, aiming at innovative treatments for unmet medical needs.
- Development of CRF1 receptor antagonists for stress-related disorders, targeting a novel pathway for anxiety and depression management.
- Partnership in developing VMAT2 inhibitors for potential treatment of chorea associated with Huntington’s disease, expanding therapeutic options.
- Exploration of small molecule treatments for rare pediatric diseases, emphasizing on advancing care for underserved conditions.
Neurocrine Biosciences executive team
- Mr. Kyle W. Gano Ph.D.CEO & Director
- Mr. Matthew C. Abernethy CPAChief Financial Officer
- Dr. Jude Onyia Ph.D.Chief Scientific Officer
- Mr. Eric S. BenevichChief Commercial Officer
- Dr. Eiry Wyn Roberts M.D.Strategic Advisor
- Dr. Wylie W. Vale Ph.D.Co-Founder
- Dr. Lawrence Steinman BA, M.D., Ph.D.Co-Founder of Neurocrine
- Mr. Lewis ChoiChief Information Officer
- Jane SorensenHead of Investor Relations
- Mr. Darin M. Lippoldt Esq.Chief Legal Officer & Corporate Secretary